Peruvian Antitrust Body Imposes $135 Million Fine on Drug Companies for Price Collusion
Table of Contents
A sweeping investigation into pharmaceutical procurement has resulted in over $135 million in fines levied against 13 companies and five executives in Peru, as the Commission for the Defense of Free Competition of Indecopi found evidence of widespread collusion to inflate prices on essential medicines. The penalties, announced following a years-long probe, underscore a growing global concern over anti-competitive practices within the healthcare industry.
Decades of Coordinated Bidding
The investigation, spanning from December 2006 to February 2020, revealed a coordinated effort among laboratories and distributors to manipulate the outcome of state-run drug purchasing tenders. Indecopi reported that the companies strategically coordinated their proposals and abstentions to secure contracts for vital pharmaceutical products destined for public hospitals. The total financial sanction exceeds S/ 539 million (approximately $135 million USD) for the companies, with an additional S/ 1.4 million (approximately $350,000 USD) in fines imposed on the five implicated executives.
Essential Medicines Affected
The cartel’s actions impacted the availability and cost of a wide range of critical medications, including:
- Sodium chloride: Used for medication administration, fluid replacement, and rehydration.
- Antibiotics: Such as amoxicillin and azithromycin, for treating common infections.
- Antineoplastics: Including Paclitaxel and Temozolamide, used in cancer treatment.
- Immunosuppressants: Like methotrexate, vital for treating acute leukemias and head and neck cancer.
- Antianemics: Such as ferrous sulfate, an essential iron supplement.
The manipulation of these tenders directly affected access to treatment for vulnerable populations relying on public healthcare services.
Sophisticated Tactics to Evade Detection
Indecopi’s investigation, which analyzed 23 tenders issued by the Ministry of Health and EsSalud, uncovered a deliberate attempt to conceal illicit activities. Investigators meticulously reviewed files, emails, chats, telephone conversations, statements, and economic information to build their case. According to the findings, the sanctioned companies “agreed on their positions to define how they would be favored with the distribution of medicines.”
To avoid detection, the companies reportedly eschewed traditional communication methods, opting instead for discreet group meetings and bilateral negotiations. A senior official stated that the companies actively avoided exchanging emails or meeting in person, and employed “exclusive cryptic language and nicknames” to mask their identities. This level of sophistication highlights the premeditation and systemic nature of the collusion.
Impact on Public Funds
Indecopi emphasized that such anti-competitive behavior is particularly damaging when it involves state contracts. “According to the Free Competition Law, one of the most harmful anti-competitive behaviors are agreements between bidders not to compete and, instead, share the tenders called by the State for the contracting of goods and services,” the agency stated.
The agency further clarified that these illegal practices lead to excessive expenses in the public budget, ultimately resulting in higher prices for essential medicines. A visual representation of the cost increases resulting from the collusion would be beneficial here.
Appeal Process and Next Steps
The initial decision can be appealed before the Specialized Chamber for the Defense of Competition of the Indecopi Court, representing the final administrative avenue for review. Indecopi clarified that any further legal challenges can only be pursued within the Peruvian Judiciary after the administrative process has been fully exhausted, as stipulated by the Free Competition Law.
This case serves as a stark reminder of the importance of robust oversight and enforcement in ensuring fair competition within the pharmaceutical sector and protecting public resources.
